Published in Viruses on January 27, 2010
Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget (2015) 0.98
Cardiac applications of optogenetics. Prog Biophys Mol Biol (2014) 0.95
Optogenetics' promise: pacing and cardioversion by light? Future Cardiol (2014) 0.91
Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors. FASEB J (2013) 0.89
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res (2015) 0.89
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34
Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med (1953) 9.43
Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med (2006) 8.98
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 7.12
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol (1996) 4.67
Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 4.36
Production and characterization of adeno-associated viral vectors. Nat Protoc (2006) 4.11
Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation (1998) 3.92
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res (2006) 3.63
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol (2003) 3.25
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 3.19
Self-complementary AAV vectors; advances and applications. Mol Ther (2008) 3.10
Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther (1993) 3.02
Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol (2001) 2.72
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 2.70
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 2.67
Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation (2000) 2.65
Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet (1998) 2.65
Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A (2000) 2.45
Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet (2004) 2.36
Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med (2004) 2.35
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther (2006) 2.33
Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol (2007) 2.33
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther (2005) 2.21
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 2.19
Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail (2008) 2.09
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res (2006) 2.07
Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science (1989) 1.95
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study. J Am Coll Cardiol (1995) 1.86
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 1.86
Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol (2001) 1.83
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation (1999) 1.82
Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther (2007) 1.81
Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol (1997) 1.79
Gene therapy in heart failure. Circ Res (2008) 1.79
A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res (2004) 1.76
Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis (1991) 1.75
Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A (2006) 1.74
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther (2008) 1.73
Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation (2006) 1.70
Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol (2004) 1.70
Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv (2009) 1.67
5' CArG degeneracy in smooth muscle alpha-actin is required for injury-induced gene suppression in vivo. J Clin Invest (2005) 1.62
Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol (1998) 1.62
Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol (2007) 1.60
Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther (2005) 1.59
Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther (2007) 1.56
Improved adenovirus vectors for infection of cardiovascular tissues. J Virol (2001) 1.55
Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler Thromb Vasc Biol (2000) 1.51
Dilated cardiomyopathy: a review. J Clin Pathol (2008) 1.50
Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther (2004) 1.50
Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol (2006) 1.43
Current status of cardiovascular gene therapy. Mol Ther (2007) 1.41
'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther (2003) 1.35
Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med (2004) 1.35
Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci U S A (2005) 1.35
Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol (2007) 1.31
Adenoviral vectors for gene transfer and therapy. J Gene Med (2004) 1.31
Viral causes of human myocarditis. Arch Cardiovasc Dis (2009) 1.28
Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther (2001) 1.28
Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J Virol (2006) 1.27
Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol (2007) 1.26
Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther (2002) 1.26
Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation (2004) 1.26
The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem (2009) 1.25
Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci U S A (2004) 1.25
A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther (2008) 1.23
Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res (2006) 1.22
A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther (2004) 1.22
Lentiviral nuclear import: a complex interplay between virus and host. Bioessays (2007) 1.22
The coxsackie-adenovirus receptor--a new receptor in the immunoglobulin family involved in cell adhesion. Curr Top Microbiol Immunol (2004) 1.22
Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther (2004) 1.20
A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol (2003) 1.20
Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol (2004) 1.20
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther (2006) 1.18
In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res (1993) 1.18
A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther (2000) 1.17
Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther (2002) 1.17
Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol Ther (2007) 1.15
A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem (1995) 1.15
Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet (2002) 1.13
Critical analysis of coronary artery bypass graft surgery: a 30-year journey. J Am Coll Cardiol (1998) 1.12
Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation (2004) 1.12
Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation (2008) 1.10
Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther (2004) 1.09
Transforming growth factor-beta1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol (2004) 1.93
Outside and in: development of neuronal excitability. Curr Opin Neurobiol (2002) 1.23
Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome. Am J Hum Genet (2011) 0.88
Ex vivo modeling of chemical synergy in prenatal kidney cystogenesis. PLoS One (2013) 0.84
Plasmid-mediated gene therapy for cardiovascular disease. Cardiovasc Res (2011) 0.80
Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas. PLoS One (2013) 0.79
Beta-adrenoceptor blockade markedly attenuates transgene expression from cytomegalovirus promoters within the cardiovascular system. Arterioscler Thromb Vasc Biol (2006) 0.78
Characterization of a right atrial subsidiary pacemaker and acceleration of the pacing rate by HCN over-expression. Cardiovasc Res (2013) 0.76
[Experimental study on BMSCs transfected by endogene inhibiting hypertrophic scar]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2008) 0.75
Simplified bookmark method for local medical school examinations. Med Educ (2011) 0.75
Periluminal expression of a secreted transforming growth factor-β type II receptor inhibits in-stent neointima formation following adenovirus-mediated stent-based intracoronary gene transfer. Hum Gene Ther (2014) 0.75